![](/images/Company_Logo/company_logo_default.png)
Targepeutics Inc Profile last edited on: 6/5/2019
CAGE: 38KV1
UEI: JN8ARN7JB9M5
Business Identifier: Targeted therapies for cancers and asthma Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 10
County: Dauphin
Congr. District: 10
County: Dauphin
Public Profile
Targepeutics is a biopharmaceutical company developing selective molecularly targeted therapeutics to fight and diagnose cancer and other diseases. The firm's lead compound, GB-13, is reported as advancing toward a Phase I clinical trial for several cancer targets. GB-13 is a genetically engineered recombinant protein that specifically binds and destroys cancer cells with minimal normal cell damage. Management of the firm also report that they have licensed related technology for a cancer immunotherapy that is in Phase III clinical trials.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
10-14Revenue Range
1M-1.5MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2023 | 1 | NIH | $330,000 | |
Project Title: Development of GB13 for the Treatment of Pediatric Diffuse Intrinsic Pontine Glioma | ||||
2011 | 1 | NIH | $199,785 | |
Project Title: Tas::75 0849::Tas Topic 255 Development of Gb13 as a Novel Glioblastoma Therapy | ||||
2000 | 1 | NIH | $100,000 | |
Project Title: Glioblast-13: A Novel Anti-Brain Tumor Therapeutic |
Key People / Management
Darren Wolfe -- CEO
Stephen Abramson
Sil Lutkewitte
Stephen Abramson
Sil Lutkewitte
Company News
There are no news available.